{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:10:13Z","timestamp":1790939413112,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s00277-010-0948-7","type":"journal-article","created":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T10:28:00Z","timestamp":1271068080000},"page":"861-871","source":"Crossref","is-referenced-by-count":20,"title":["Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases"],"prefix":"10.1007","volume":"89","author":[{"given":"Lina","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Jacob","family":"Schuringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edo","family":"Vellenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,13]]},"reference":[{"key":"948_CR1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730\u2013737","journal-title":"Nat Med"},{"key":"948_CR2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645\u2013648","journal-title":"Nature"},{"key":"948_CR3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.genom.3.032802.115046","volume":"3","author":"LM Kelly","year":"2002","unstructured":"Kelly LM, Gilliland DG (2002) Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3:179\u2013198","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"948_CR4","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658\u20136661","journal-title":"J Med Chem"},{"key":"948_CR5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M (2003) BCR\u2013ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690\u2013698","journal-title":"Blood"},{"key":"948_CR6","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2403775","volume":"19","author":"C Gambacorti-Passerini","year":"2005","unstructured":"Gambacorti-Passerini C, Gasser M, Ahmed S, Assouline S, Scapozza L (2005) Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia 19:1267\u20131269","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"948_CR7","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.leukres.2003.10.005","volume":"28","author":"RA Etten Van","year":"2004","unstructured":"Van Etten RA (2004) Mechanisms of transformation by the BCR\u2013ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 28(Suppl 1):S21\u2013S28","journal-title":"Leuk Res"},{"key":"948_CR8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","volume":"66","author":"MM Schittenhelm","year":"2006","unstructured":"Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC (2006) Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66:473\u2013481","journal-title":"Cancer Res"},{"key":"948_CR9","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1038\/sj.onc.1208079","volume":"23","author":"PA Bromann","year":"2004","unstructured":"Bromann PA, Korkaya H, Courtneidge SA (2004) The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 23:7957\u20137968","journal-title":"Oncogene"},{"key":"948_CR10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.leu.2404547","volume":"21","author":"M Okamoto","year":"2007","unstructured":"Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T (2007) Lyn is an important component of the signal transduction pathway specific to FLT3\/ITD and can be a therapeutic target in the treatment of AML with FLT3\/ITD. Leukemia 21:403\u2013410","journal-title":"Leukemia"},{"key":"948_CR11","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2007-04-082099","volume":"111","author":"SC Dos","year":"2008","unstructured":"Dos SC, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C (2008) A critical role for Lyn in acute myeloid leukemia. Blood 111:2269\u20132279","journal-title":"Blood"},{"key":"948_CR12","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/blood.V92.2.596","volume":"92","author":"MC Bene","year":"1998","unstructured":"Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, Ludwig WD, Matutes E, Orfao A, Sperling C, van't Veer MB (1998) The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 92:596\u2013599","journal-title":"Blood"},{"key":"948_CR13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.leukres.2007.08.019","volume":"32","author":"AS Advani","year":"2008","unstructured":"Advani AS, Rodriguez C, Jin T, Jawde RA, Saber W, Baz R, Kalaycio M, Sobecks R, Sekeres M, Tripp B, Hsi E (2008) Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leuk Res 32:913\u2013918","journal-title":"Leuk Res"},{"key":"948_CR14","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V95.2.726","volume":"95","author":"A Beghini","year":"2000","unstructured":"Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E, Mecucci C (2000) C-kit mutations in core binding factor leukemias. Blood 95:726\u2013727","journal-title":"Blood"},{"key":"948_CR15","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/pbc.21368","volume":"50","author":"EA Kolb","year":"2008","unstructured":"Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA (2008) Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 50:1198\u20131206","journal-title":"Pediatr Blood Cancer"},{"key":"948_CR16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.leukres.2008.09.027","volume":"33","author":"C Ustun","year":"2009","unstructured":"Ustun C, Corless CL, Savage N, Fiskus W, Manaloor E, Heinrich MC, Lewis G, Ramalingam P, Kepten I, Jillella A, Bhalla K (2009) Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res 33:735\u2013741","journal-title":"Leuk Res"},{"key":"948_CR17","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.exphem.2007.07.001","volume":"35","author":"D Gosliga van","year":"2007","unstructured":"van Gosliga D, Schepers H, Rizo A, van der Kolk D, Vellenga E, Schuringa JJ (2007) Establishing long-term cultures with self-renewing acute myeloid leukemia stem\/progenitor cells. Exp Hematol 35:1538\u20131549","journal-title":"Exp Hematol"},{"key":"948_CR18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-1-59745-418-6_14","volume":"538","author":"JJ Schuringa","year":"2009","unstructured":"Schuringa JJ, Schepers H (2009) Ex vivo assays to study self-renewal and long-term expansion of genetically modified primary human acute myeloid leukemia stem cells. Methods Mol Biol 538:287\u2013300","journal-title":"Methods Mol Biol"},{"key":"948_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrfmmm.2004.08.015","volume":"572","author":"W Lawley","year":"2005","unstructured":"Lawley W, Hird H, Mallinder P, McKenna S, Hargadon B, Murray A, Bradding P (2005) Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis. Mutat Res 572:1\u201313","journal-title":"Mutat Res"},{"key":"948_CR20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/sj.leu.2400812","volume":"11","author":"S Yokota","year":"1997","unstructured":"Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kahsima K, Matsuo Y, Naoe T (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11:1605\u20131609","journal-title":"Leukemia"},{"key":"948_CR21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1084\/jem.20041024","volume":"200","author":"JJ Schuringa","year":"2004","unstructured":"Schuringa JJ, Chung KY, Morrone G, Moore MA (2004) Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med 200:623\u2013635","journal-title":"J Exp Med"},{"key":"948_CR22","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1158\/1535-7163.MCT-06-0446","volume":"6","author":"S Nam","year":"2007","unstructured":"Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R (2007) Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther 6:1400\u20131405","journal-title":"Mol Cancer Ther"},{"key":"948_CR23","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","volume":"12","author":"W Fiskus","year":"2006","unstructured":"Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K (2006) Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 12:5869\u20135878","journal-title":"Clin Cancer Res"},{"key":"948_CR24","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/blood-2006-09-045039","volume":"109","author":"TK Nguyen","year":"2007","unstructured":"Nguyen TK, Rahmani M, Harada H, Dent P, Grant S (2007) MEK1\/2 inhibitors sensitize Bcr\/Abl+ human leukemia cells to the dual Abl\/Src inhibitor BMS-354\/825. Blood 109:4006\u20134015","journal-title":"Blood"},{"key":"948_CR25","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1038\/sj.onc.1210179","volume":"26","author":"K Nunoda","year":"2007","unstructured":"Nunoda K, Tauchi T, Takaku T, Okabe S, Akahane D, Sashida G, Ohyashiki JH, Ohyashiki K (2007) Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors. Oncogene 26:4179\u20134188","journal-title":"Oncogene"},{"key":"948_CR26","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/cncr.22215","volume":"107","author":"RH Alvarez","year":"2006","unstructured":"Alvarez RH, Kantarjian HM, Cortes JE (2006) The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107:1918\u20131929","journal-title":"Cancer"},{"key":"948_CR27","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1038\/sj.onc.1205398","volume":"21","author":"SG Rane","year":"2002","unstructured":"Rane SG, Reddy EP (2002) JAKs, STATs and Src kinases in hematopoiesis. Oncogene 21:3334\u20133358","journal-title":"Oncogene"},{"key":"948_CR28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.critrevonc.2007.05.005","volume":"63","author":"KT Doepfner","year":"2007","unstructured":"Doepfner KT, Boller D, Arcaro A (2007) Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Crit Rev Oncol Hematol 63:215\u2013230","journal-title":"Crit Rev Oncol Hematol"},{"key":"948_CR29","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.4049\/jimmunol.180.4.2045","volume":"180","author":"LA Thoren","year":"2008","unstructured":"Thoren LA, Liuba K, Bryder D, Nygren JM, Jensen CT, Qian H, Antonchuk J, Jacobsen SE (2008) Kit regulates maintenance of quiescent hematopoietic stem cells. J Immunol 180:2045\u20132053","journal-title":"J Immunol"},{"key":"948_CR30","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1158\/1078-0432.CCR-07-5134","volume":"14","author":"D Kent","year":"2008","unstructured":"Kent D, Copley M, Benz C, Dykstra B, Bowie M, Eaves C (2008) Regulation of hematopoietic stem cells by the steel factor\/KIT signaling pathway. Clin Cancer Res 14:1926\u20131930","journal-title":"Clin Cancer Res"},{"key":"948_CR31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-2141.1995.tb08418.x","volume":"89","author":"S Matozaki","year":"1995","unstructured":"Matozaki S, Nakagawa T, Kawaguchi R, Aozaki R, Tsutsumi M, Murayama T, Koizumi T, Nishimura R, Isobe T, Chihara K (1995) Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t(8;21) who acquired monosomy 17 during disease progression. Br J Haematol 89:805\u2013811","journal-title":"Br J Haematol"},{"key":"948_CR32","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/leu.2008.61","volume":"22","author":"H Becker","year":"2008","unstructured":"Becker H, Pfeifer D, Afonso JD, Nimer SD, Veelken H, Schwabe M, Lubbert M (2008) Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the \u2018second hit\u2019 hypothesis. Leukemia 22:1792\u20131794","journal-title":"Leukemia"},{"key":"948_CR33","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107:4532\u20134539","journal-title":"Blood"},{"key":"948_CR34","first-page":"920","volume":"89","author":"A Beghini","year":"2004","unstructured":"Beghini A, Ripamonti CB, Cairoli R, Cazzaniga G, Colapietro P, Elice F, Nadali G, Grillo G, Haas OA, Biondi A, Morra E, Larizza L (2004) KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 89:920\u2013925","journal-title":"Haematologica"},{"key":"948_CR35","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","volume":"24","author":"P Paschka","year":"2006","unstructured":"Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24:3904\u20133911","journal-title":"J Clin Oncol"},{"key":"948_CR36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.exphem.2005.01.004","volume":"33","author":"LJ Robinson","year":"2005","unstructured":"Robinson LJ, Xue J, Corey SJ (2005) Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp Hematol 33:469\u2013479","journal-title":"Exp Hematol"},{"key":"948_CR37","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.exphem.2008.01.002","volume":"36","author":"CM Orschell","year":"2008","unstructured":"Orschell CM, Borneo J, Munugalavadla V, Ma P, Sims E, Ramdas B, Yoder MC, Kapur R (2008) Deficiency of Src family kinases compromises the repopulating ability of hematopoietic stem cells. Exp Hematol 36:655\u2013666","journal-title":"Exp Hematol"},{"key":"948_CR38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/BJ20080102","volume":"415","author":"S Gueller","year":"2008","unstructured":"Gueller S, Gery S, Nowak V, Liu L, Serve H, Koeffler HP (2008) Adaptor protein Lnk associates with Tyr(568) in c-Kit. Biochem J 415:241\u2013245","journal-title":"Biochem J"},{"key":"948_CR39","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.0606238104","volume":"104","author":"J Seita","year":"2007","unstructured":"Seita J, Ema H, Ooehara J, Yamazaki S, Tadokoro Y, Yamasaki A, Eto K, Takaki S, Takatsu K, Nakauchi H (2007) Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction. Proc Natl Acad Sci U S A 104:2349\u20132354","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00277-010-0948-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T17:37:28Z","timestamp":1591205848000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-010-0948-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,13]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1007\/s00277-010-0948-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,13]]}}}